Cytogenetic studies (CG) of 475 chronic lymphocytic leukemia (CLL) cases showed trisomy 1 2 in 6.1 % or 26% of patients with abnormal karyotypes. Fluorescence in situ hybridization (FISH) detected trisomy 1 2 in 35% of 11 7 CLL patients. Only 34.6% of cases detected by FISH were detected by CG. Twelve patients had low levels of trisomic cells (4% to 1 1 %) relative to clonal B cells (47.5% to 86%).
Fluorescent in situ hybridization (FISH) is a rapid method for detecting chromosomal abnormalities in nondividing interphase cells or during metaphase. Greater numbers of cells can be evaluated than by conventional cytogenetic analysis, and an accurate assessment of the proportion of abnormal cells present can be made.',' When the cytogenetic abnormality is known, the presence of minimal residual disease can be detected using FISH. [9] [10] [11] [12] In this study, conventional karyotype analysis was performed in 475 CLL samples. FISH was used in 117 CLL patients to detect trisomy 12 using a centromeric probe for chromosome 12. Cytogenetic results were then compared with FISH, and correlated with clinical characteristics of the patients. Lineage-restriction was investigated using fluorescence-activated cell sorter (FACS)-separated cells selected by immunophenotype followed by FISH,I2 and the same combination of techniques was used to study minimal residual disease in I O patients with known trisomy 12 in remission.
MATERIALS AND METHODS

Patient Population
Heparinized peripheral blood and/or bone marrow samples were obtained from CLL patients at the M.D. Anderson Cancer Center Leukemia Clinic from January 1991 to September 1992 (n = 61). Fixed bone marrow cells were obtained from archived material prepared from January 1987 to January 1991 ( n = 56). Most samples were collected at the patient's first M.D. Anderson presentation. Controls were ( I ) the buffy coat cells of normal volunteers (n = 13) and (2) archived material from CLL patients with abnormalities other than trisomy 12 (n = 17).
Approval was obtained from the Institutional Review Board for these studies. Patients and volunteers were informed that blood and/ or bone marrow samples were obtained for research purposes, at the same time as routine samples were obtained, and that their privacy would be protected.
FISH
The hybridization probe was a biotinylated asatellite DNA fragment of approximately 175 bp that binds specifically
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to repeated DNA sequences in the centromeric region of human chromosome 12. The probe was originally generated by primer-directed in vitro DNA amplification using the polymerase chain reaction (PCR) from flow-sorted metaphase chromosomes 12 using primers WAI and WA2 as described el~ewhere.'~,'~ In later experiments, we used a recombinant DNA template containing the 173-bp Hind111 fragment in phosphate-buffered saline (PBS; Stratagene, San Diego, CA). Total human alphoid blocking DNA was generated using human genomic DNA and primers WAl and WA2 as described previBufi coat, bone marrow aspirates, and, in some cases, mononuclear cells separated over a Ficoll-Hypaque density gradient (Lymphocyte Separation Medium; Organon Teknika, Durham, NC) were fixed in 3: 1 methanokacetic acid and stored at -20°C.
The cell suspensions were dropped on glass slides and air-dried.
The slides were washed sequentially in 0.1 N HCL with 0.1% Triton X-100, 2X saline sodium citrate (SSC), PBS, PBS with 1% formaldehyde, PBS, and then 2X SSC. The slides were then denatured in 70% formamide 2X SSC solution at 70°C for 4 to 6 minutes. These were dehydrated for 1 minute each in 70%, 85%, and 100% ethanol, and then air-dried. One microliter of the probe was diluted in 9 pL of hybridization mixture (7 pL master mix [50% formamide in 2X SSC and glycerin with 1 fiL of salmon sperm DNA per 10 pL], 1 pL of distilled water, and I pL of a-satellite-blocking DNA), denatured at 70°C for 5 minutes, and then placed in ice. The hybridization mixture (IO pL) was dropped on the slide, cover slipped, sealed with rubber cement, and incubated at 37°C overnight.
The slides were washed in 42°C 50% formamide in 2X SSC for 20 minutes, which was followed by two 15-minute washes with phosphate neutral buffer (PN) at 37°C. The slides were incubated with PN containing 5% nonfat dry milk (PNM) for 5 minutes, then incubated with 20 pL avidin-fluorescein conjugate (Vector Laboratories, Burlingame, CA) ( 5 pg/mL PNM) for 20 minutes at room temperature (RT), and washed in PN twice. If the hybridization signal was not detectable at this point, it was amplified with biotinylated anti-avidin (Vector Laboratories) ( 5 pg/mL PNM) incubated for 20 minutes at RT, followed by another layer of avidin-fluorescein isothiocyanate (FITC). Up to two amplifications were performed. The nuclei were counterstained with propidium iodide (0.25 pg/mL antifade). Hybridization signals were counted in 200 to 500 cells with a fluorescence microscope (Nikon Labophot 2,60X planar objective) with a 5 I O nm filter (Nikon, Tokyo, Japan).
Cytogenetics
Both peripheral blood and bone marrow samples were used. Cultures were initiated and samples incubated for 24, 48, and 72 hours at 37°C. Among the cultures were one peripheral blood culture stimulated with phytohemagglutinin (PHA; Burroughs-Wellcome, Greenville, NC) and one bone marrow sample stimulated with LPS (GIBCO, Grand Island, NY) for 72 hours. Ham's FIO tissue culture medium (GIBCO) supplemented with 10% fetal calf serum (FCS; Intergen, Purchase, NY) was used.
After the designated culture periods, the samples were harvested using established cytogenetic techniques, which included a 30-minute hypotonic treatment (0.057 mol/L KCI) and a 30-minute fixation in 3: 1 methano1:acetic acid fixative. The cell preparations were air-dried and the metaphases G-banded using a trypsin (Intergen, Purchase, NY) pretreatment and Gurr's Giemsa stain (Biomedical Specialties, Santa Monica, CA).
The slide preparations from all cultures were scored for analyzable metaphases. A maximum of 25 G-banded metaphases from the unstimulated and LPS-stimulated bone marrow and/or from the unstimulated peripheral blood cultures were analyzed. An additional 10 to 25 metaphases were analyzed from PHA-sbmulated peripheral ously.14J5 Cellpreparation.
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blood cultures. Two karyotypes were made for each type of metaphase found and the chromosomes arranged according to ISCN.I6
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Data Analysis
For comparison of distinct variables between two groups, data were analyzed using the x2 test. SuMvd curves were calculated with the method of Kaplan and Meier" and their significance determined by using logrank analysis.18 Time to progression was calculated from the initiation of treatment. Actuarial survival was measured from the time of diagnosis.
RESULTS
Cytogenetics
Conventional cytogenetic analysis by G-banding was performed in 475 C L L patient samples (Table 1) . Evaluable metaphases were present in 78%. Abnormal karyotypes were identified in 3 1 % of cases with evaluable metaphases. Of those, 29 (7.8% of evaluable, 6.1% of all patients studied) had trisomy 12 alone in one or more metaphases (12.3% ofabnormal karyotypes) o r in combination with other abnormalities ( 13.2% of abnormal karyotypes) a n d 6.2% (I .9% of evaluable) had structural abnormalities of chromosome 12. Other common chromosomal abnormalities identified were 1 1 q-(1 7% of abnormal karyotypes), 14q+ (8%), 13q-(7%), t(l1;14) (3%), -16 (3%), and i(17q) (2%).
(6%), 6q-(4%), -17 (4%), +/-19 (4%), +/-18 (4%), +/-21 
FISH
One hundred seventeen patients were evaluated using FISH. Normal control cells (n = 13) had one hybridization signal in 3%, two signals in 94.6%, and three signals in 2.2% of the cells (range, 0.8% to 4.0%; 99% confidence intervals, 1.4% to 3.0%). Archived patient samples with cytogenetic abnormalities other than trisomy 12 had an average of 2.5% of cells with one signal, 92.0% with two signals, and 3.5% with three signals (99% confidence intervals, 1.7% to 6.7%). Fresh samples were therefore considered positive for trisomy 12 with 24% cells with three signals and stored samples at 27%. The samples were considered evaluable if hybridization was present in 290% of cells or less than 20% of cells had zero or one signal. All of the fresh samples were interpretable; however, approximately one-third of the archived samples were not interpretable based on these criteria (primarily samples 2 2 years old). The confidence intervals for controls were identical for both of the two probes used.
Trisomy 12 was present in 41 of 117 patients (35%). The median percentage of cells with three hybridization signals was 38.7% (range, 4% to 89%). There was no correlation between the percentage of CD19+ or CD20' cells in the samples and the percentage of cells positive for trisomy 12. Low levels of trisomic cells (4% to 11%) were found in 12 patients with 47.5% to 86% circulating CD19' or CD20+ cells. In one patient with l l% trisomic cells, these cells were not detectable 8 and 9 months later during therapy, but this clone re-emerged with 5% trisomy 12 at 16 months. Follow-up studies on two patients with low-level trisomy at 3 months and 9 months did not show significant change. The Rai and Binet stages of these patients were similar to those of the other patients with trisomy
12.
Comparison (Table 2) . Trisomy 12 was not detected by cytogenetics in any case with less than 50% trisomic cells by FISH (0 of lo), compared with those with greater than 50% trisomic cells (9 of 15) (P < .02). Karyotypes were available on 4 patients with trisomy I2 less than 1 1 %; 1 was diploid and 3 had complex karyotypes without trisomy 12. Cytogenetic analysis showed trisomy 12 in one case ( 1 of 20 metaphases) in which FISH did not. This may represent the random gain of a chromosome in a metaphase spread or a level of trisomy 12 below the level of detection by FISH. 
Residual Leukemia and Restriction to B-Cell Lineage
In 6 patients in complete remission by National Cancer Institute (NCI) criteria (hemoglobin > 11 g/dL, lymphocytes <4,OOO/pL, neutrophils > 1,5OO/pL, and platelets > 150,000/ pL), trisomy 12 was still detectable (Table 3 ). Blood or bone marrow was tested on nine occasions, with a median of 6.5% of mononuclear cells with trisomy 12 (range, 4.3% to 65%). In four of these patients, malignant cells were enriched by sorting CD 19+ or CD 19+5+ cells. Trisomy 12 was present in a median of 52% of cells (range, 7% to 62.5%). With this technique, in one case 7% trisomy was detected in 0.2% of CD 19' cells, or less than 1 cell in 5,000 was detected (Table  3 ). Five patients with partial remissions also had detectable trisomy 12 by FISH on unseparated blood or bone marrow or in CD19' or CD19'5' cells. Two patients underwent autologous bone marrow harvests in remission. The unmanipulated marrows had 6% and 8% trisomy 12. After the samples were immunopurged with an anti-CD I9 antibody, trisomy 12 was not detected above background levels.
T cells from 10 samples from 9 patients with trisomy 12 were sorted (CDS'CD19-or CD3+CD19-) and did not display trisomy 12 (median 3.8% in T cells v mean 7 1% in B cells).
Clinical Correlat ion
Clinical characteristics of patients with trisomy 12 identified by FISH were compared with those of patients without Comparison of clinical characteristics of patients with trisomy 12 by FISH, patients with diploid karyotypes without trisomy 12 by FISH, and patients with other chromosomal abnormalities without trisomy 12 by FISH.
Abbreviations: WBC, white blood cell count; CR, complete remission; PR, partial remission; NR, no response; ED, early death. trisomy 12, patients with diploid karyotypes (n = 28), and patients with abnormal karyotypes other than trisomy 12 (n = 17) ( Table 4 ). Advanced Binet stage was seen more frequently in patients with trisomy 12 than in diploid patients (P < .02). There was a trend for trisomy 12 patients to have lower hemoglobin levels than diploid patients (P < . 1). Trisomy I2 patients were more likely to have had prior treatment than patients with diploid karyotypes (18 of 41 v 6 of 28) (P < .02). The overall response rate to fludarabine was comparable to that found in previous studies." The complete and partial remission rate was greater in patients with trisomy 12 than in those with other abnormalities (20 of 29 v 4 of 12) (P < .05), but was equivalent to that in patients with diploid karyotypes. When only patients who had prior treatment were considered, patients with trisomy 12 had a higher complete and partial remission rate than those without trisomy 12 (1 1 of 18 v 5 of 22) (P < .02). Previously untreated patients with trisomy 12 had an increased incidence of splenomegaly and were predominantly male ( I 5 of 18 v 24 of 44) (P < .04).
Median survival from the time of diagnosis was significantly shorter in patients with trisomy 12 by FISH (7.8 years) and in patients with other abnormal karyotypes without trisomy 12 by FISH (5.5 years) than in patients with diploid karyotypes without trisomy 12 by FISH (14.4 years). The median follow-up was 4 years (Fig I) . When patients with trisomy 12 were compared with all other patients, there was no difference in survival (Fig 2) . Median time to progression after treatment with fludarabine-based regimens tended to be shorter in patients with other abnormal karyotypes (21.5 months) than in trisomy 12 patients (not reached) and diploid patients (not reached) (P = . I ) (Fig 3) .
DISCUSSION
The median overall survival for CLL patients is 9 years." The presence of clonal chromosomal abnormalities predicts for a shorter overall survival time. Specifically, complex abnormalities, increased percentages of abnormal metaphases, abnormalities of the long arm of chromosome 14, and trisomy 12 have been associated with shortened survival. Although Trisomy 12 was associated with a shorter therapy-free survival, but not with overall ~urvival.~ A cooperative study reported cytogenetic analyses on 433 CLL patients. Trisomy 12 was present in 3 1 % of abnormal karyotypes ( 17% of evaluable patients, 15 .5% of all patients). In univariate analysis, trisomy 12 was significantly associated with a poorer survival rate (P < ,005). The median survival of patients with any clonal abnormalities was 7.7 years and greater than 15 years in patients with normal karyotype^.^ This study has recently been updated with similar results in 662 patients. The median survival of patients with trisomy 12 alone was approximately 7.7 years.25 We have confirmed these results with a shorter median survival in patients with trisomy 12 (7.8 years) compared with patients with diploid karyotypes (14.4 years). When these patients were treated, the response rate was similar to that of diploid patients and of patients without trisomy 12, but there was a trend for these patients to relapse sooner (Fig 3) . These findings suggest a higher proliferative rate in patients with cytogenetic abnormalities. In addition, patients in clinical remission all had residual disease, which could also contribute to the poorer survival. However, the absence of an equally sensitive marker for residual disease in patients with diploid karyotypes precludes knowledge of the level of residual disease in these patients.
We have confirmed the restriction of trisomy 12 to B cells and its absence in T cells using the combined FISH/FACS approach. Knuutila et a15 and Autio et aI6 have previously reported similar results using a combination of immunophenotyping and cytogenetic analysis. Our results obtained in 200 to 500 cells in each sample rules out even low levels of T cells with this abnormality.
Minimal residual disease was readily detected with FISH in 6 CLL patients in complete remission and in 4 patients in partial remission. Using FACS to separate CDI9'5' cells enhanced our ability to detect residual disease up to eightfold. cytogenetic abnormalities are prognostically important in CLL, approximately 50% to 70% of patients have either a diploid karyotype or insufficient metaphases for analysis. In recent studies of CLL, FISH detected a higher incidence of trisomy 12 than conventional cytogenetic^.^'-^^ A decreased overall survival was suggested in the study of Anastasi et a1,22 but was not statistically significant. With the use of FISH, we were able to detect 2.6 times as many cases of trisomy I2 as were detected with conventional cytogenetic analysis in the 83 samples studied with both techniques. This was primarily due to the detection of trisomy 12 in samples that were classified as diploid or had insufficient metaphases for conventional analysis. We identified 4 1 patients with trisomy 12. Of l l patients found to have trisomy 12 in one or more metaphases with conventional cytogenetics, 10 were confirmed with FISH. In cases oftrisomy 12 identified with FISH that were originally classified as cytogenetically diploid or as having insufficient metaphases, dividing normal T cells may have led to misleading result^.^.^ In 4 patients with trisomy 12 by FISH and additional abnormal karyotypes, 3 had low numbers of trisomic cells (7.3%, 8.5%, and 1 I%), most likely representing clonal evolution. About one-fourth of patients with trisomy 12 had a low percentage of trisomic cells, suggesting clonal evolution. This finding may also suggest that trisomy 12 is a secondary event in at least a proportion of the patients. If trisomy 12 was present in more than 50% of cells by FISH, it was more likely to also be detected with conventional cytogenetics, but in none of the samples with less than 50% trisomic cells was cytogenetic analysis successful.
Untreated patients with trisomy 12 tended to present with more splenomegaly than patients without trisomy 12. This is consistent with the more advanced stage seen in the trisomy 12 patients. Patients with trisomy 12 were also more likely to be previously treated. This may be due to the more advanced stage requiring treatment sooner, as reported by othe r~,~ or, alternatively, that this is a secondary event associated with disease progression. It is less likely that trisomy 12 develops secondary to chemotherapy.
In 1984, Han et a12 reported trisomy 12 in 63% of CLL patients with abnormal karyotypes (23.6% of evaluable pa- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
